— Know what they know.
Not Investment Advice
Also trades as: MXCT.L (LSE) · $vol 0M

MXCT NASDAQ

MaxCyte, Inc.
1W: -8.6% 1M: -15.8% 3M: -15.8% YTD: -31.0% 1Y: -33.1% 3Y: -65.3% 5Y: -92.3%
$1.07
-0.02 (-1.83%)
 
Weekly Expected Move ±5.0%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 29 · $114.6M mcap · 98M float · 0.996% daily turnover · Short 28% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$114.6M
52W Range0.643-1.87
Volume228,089
Avg Volume972,343
Beta1.53
Dividend—
Analyst Ratings
4 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOMaher Masoud
Employees91
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-29
9713 Key West Avenue
Rockville, MD 20850
US
301 944 1700
About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
Johnston John Joseph A-Award 30,421 — 2026-06-17
Johnston John Joseph A-Award 49,579 $1.13 2026-06-17
Hemrajani Rekha A-Award 30,421 — 2026-06-17
Hemrajani Rekha A-Award 49,579 $1.13 2026-06-17
Erck Stanley C A-Award 30,421 — 2026-06-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms